Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple anglesDavid T. Hoang, Marja T. Nevalainen, Kenneth A. Iczkowski et al.|Oncotarget|2016Cited by 123
Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.Deepak Kilari, Kenneth A. Iczkowski, Chintan Pandya et al.|PubMed|2016Cited by 44
Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 InhibitorsVindhya Udhane, Marja T. Nevalainen, Cristina Maranto et al.|Molecular Cancer Therapeutics|2019Cited by 26
Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?Paul Beinhoff, Marja T. Nevalainen, Lavannya Sabharwal et al.|Cancers|2021Cited by 24
Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment ParadigmRuben Raychaudhuri, Deepak Kilari, Matthew J. Riese et al.|Clinical Genitourinary Cancer|2017Cited by 19